Ribavirin News and Research

RSS

Ribavirin, also known as Copegus, Rebetol, Virazole, or a component of Rebetron, is a type of antiviral medicine called a nucleoside analogue. This medicine blocks the ability of the hepatitis C virus (HCV) to make more copies of itself. Ribavirin is not active against HIV. Ribavirin is used in combination with interferon alfa-2a or -2b or peginterferon alfa-2a or -2b to treat HIV infected patients who are also infected with HCV.

Interferon combined with ribavirin treatment is effective for children with chronic Hepatitis C virus

Nearly half of 118 children with chronic Hepatitis C virus (HCV) treated with a combination of interferon-alpha-2b and an optimized dose of ribavirin achieved sustained viral response, and side effects were generally mild.

3 Nov 2005

Combination of ribavirin and interferon is more effective in treating hepatitis C than using interferon alone

The researchers reviewed 72 randomized trials and 9,991 patients who had chronic hepatitis C for more than six months and were previously untreated, who had relapsed after treatment or who had not responded to other treatment.

19 Jul 2005

New UK Guidance to be issued on Hepatitis C as 'silent epidemic'

Leading medical experts from throughout the UK will be gathering in Edinburgh today and tomorrow (21-22 April 2004) to arrive at a consensus on how best to treat and manage the 'silent epidemic' of hepatitis C - a virus which is estimated to be carried by over 400,000 people in the UK and which continues to spread globally, as the majority of carriers do not realise they have been infected.

21 Jun 2005

Protocol used to treat the first known survivor of rabies without prior vaccination published

The protocol used to treat the first known survivor of rabies without prior vaccination is published in the June 16, 2005, issue of the New England Journal of Medicine. It is hoped that this approach can be replicated, tested, and provide a guide for treating this fatal condition, especially in parts of the world where the incidence of rabies is rampant.

15 Jun 2005

Researchers discover how hepatic-C virus evades immune system in acute and chronic infections

Researchers at Johns Hopkins have uncovered how a majority of the genetic changes in the hepatic-C virus, the most common cause of liver disease, allow it to evade the body's immune system during infection.

10 Jun 2005

Milk thistle not proven effective in lowering mortality in alcoholic or hepatitis B or C liver disease

While some studies found that liver-related mortality may be significantly reduced in patients treated with milk thistle, these findings were not duplicated in the higher quality clinical trials.

2 May 2005

Small number of genes can predict response to chronic hepatitis C therapy

For the first time, physicians at University Health Network and University of Toronto have identified a small subset of genes that can predict whether a patient with chronic Hepatitis C will be able to respond to current treatments.

2 May 2005

Respiratory syncytial virus affects the elderly and high-risk adults as much as influenza

Respiratory syncytial virus (RSV), primarily seen as a cause of illness in infants and children, often affects the elderly and high-risk adults as much as influenza, a study by University of Rochester Medical Center researchers demonstrates.

27 Apr 2005

Viramidine demonstrates anti-HCV Genotype 1 activity that compares favorably to Ribavirin

Dose-limiting anemia can be a prominent adverse event of therapy with pegylated interferon and ribavirin. This dose-ranging study examined whether viramidine, a liver-targeting prodrug of ribavirin, may be a safer alternative when used in combination with pegylated interferon alfa-2a/ PEG-IFN (Pegasys).

23 Apr 2005

New study to evaluate Pegasys and Copegus to treat hepatitis C in liver transplant patients

Roche has initiated a new study to evaluate treatment strategies to reduce post-transplant recurrence of hepatitis C infection with the most prescribed hepatitis C treatment combination in the U.S., Pegasys (peginterferon alfa-2a) and Copegus (ribavirin, USP).

21 Mar 2005

New approaches for the treatment of chronic hepatitis C

Data from two ongoing studies testing new approaches for the treatment of chronic hepatitis C was presented at the annual meeting of the American Association for the Study of Liver Diseases (AASLD) this afternoon.

1 Nov 2004

Pegasys with ribavirin combo may best for reducing hepatitis C viral levels

Interim study results indicate a certain drug combination treatment may suppress the hepatitis C virus more quickly than another.

1 Nov 2004

Respiratory therapists are at an increased risk of developing asthma

Respiratory therapists are at an increased risk of developing asthma and asthma-related symptoms due to their involvement in the diagnosis and treatment of patients with respiratory conditions.

11 Oct 2004

Teva Pharmaceuticals granted final approval for Ribavirin capsules

Teva Pharmaceutical Industries has announced that the U.S. Food and Drug Administration has granted final approval for the Company’s ANDA for Ribavirin Capsules, 200 mg. Shipment of this product is expected to begin immediately.

5 Oct 2004

Lassa Fever, not seen in US for 15 years re-emerges

The New Jersey Department of Health and Senior Services reported today that a 38-year-old Mercer County man died on August 28 from an acute viral disease called Lassa fever, a condition that is rare in the U.S., but endemic to West Africa.

23 Sep 2004

Neck surgeons brush up on West Nile virus

Neck Surgery Foundation Annual Meeting & OTO EXPO, being held September 19-22, 2004, at the Jacob K. Javits Convention Center, New York City, NY.

17 Sep 2004

Widely used antimalarial drug exhibits antiviral activity against the SARS

Virologists from the Katholieke Universiteit Leuven in Belgium report that chloroquine, a widely used antimalarial drug, exhibits antiviral activity against the SARS coronavirus. Chloroquine is an inexpensive and safe drug available worldwide.

5 Sep 2004

Peginterferon and Ribavirin combination promising for those with HIV and HCV

Since the introduction of highly active combination drug therapy for HIV, liver failure attributable to infection with the hepatitis C virus (HCV) has become a leading cause of death among those infected with the virus that causes AIDS.

22 Aug 2004

Study shows safe, effective therapy for previously untreated patients with HIV & hepatitis C

An international study with nearly 900 patients co-infected with Human Immunodeficiency Virus (HIV) and hepatitis C virus (HCV) has shown that HCV can be treated effectively and safely, without compromising the patient’s HIV therapy.

29 Jul 2004

New drug combination more effective than the previous generation of hepatitis C/HIV therapy

A new study reveals the highest efficacy rates ever reported among patients co-infected with hepatitis C and HIV treated with pegylated interferon and ribavirin.

28 Jul 2004